Matches in SemOpenAlex for { <https://semopenalex.org/work/W2604797481> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W2604797481 endingPage "3051" @default.
- W2604797481 startingPage "3051" @default.
- W2604797481 abstract "3051 Background: Blinatumomab (AMG 103) is an investigational, bispecific, T cell engaging (BiTE) antibody targeting CD19-expressing B cells. We describe the exposure-pharmacodynamic (PD) response of blinatumomab in patients with NHL, using a quantitative pharmacology approach. Methods: In a phase 1 study, 76 patients with NHL received blinatumomab by continuous intravenous infusion (cIV) at doses of 0.5 to 90 μg/m 2 /d in 4- or 8-week cycles. Pharmacokinetics (PK) was determined. PD responses evaluated included lymphocytes and cytokines measured during treatment, and sum of the products of the greatest diameters of tumor size in lymph nodes (SPD) at the end of treatment. Blinatumomab concentration at steady state (C ss ) and the cumulative area under the concentration (AUC cum )–time curve over the period before the evaluation of SPD were used to evaluate the exposure-SPD relationship. Results: Blinatumomab showed linear PK. Early PD responses were characterized by B cell depletion, T cell redistribution, and transient cytokine release. Following cIV at doses from 0.5 to 90 μg/m 2 /d, B cells declined at a first-order rate with a dose-dependent rate constant, ranging from 0.16 to 1.0 h -1 . Complete B cell depletion was achieved within 48 hours at doses ≥5 μg/m 2 /d. A dose-independent decrease in T cell counts was observed within 24 hours after dosing, and T cells returned to baseline within 2 weeks of treatment. Cytokine elevation occurred in some patients and was dose-dependent. Blinatumomab exposure-SPD relationship was best described by an inhibitory E max model (E = E 0 -(I max *C)/(IC 50 +C)). According to the model estimation, a 50% reduction in SPD would be achieved when C ss is 2141 pg/mL and AUC cum is 1381 h*μg/L, equivalent to a blinatumomab dose of 54 µg/m 2 /d given over 27 days. Conclusions: B lymphocytes were completely depleted from the circulation at blinatumomab doses ≥5 μg/m 2 /d. Depletion was faster at higher doses. Higher blinatumomab C ss and AUC cum were associated with better tumor reduction. Tissue accessibility may explain the higher dose requirement for SPD reduction versus peripheral B cell depletion. The PK/PD model has utility for the design of future studies of blinatumomab in NHL. Clinical trial information: NCT00274742." @default.
- W2604797481 created "2017-04-14" @default.
- W2604797481 creator A5008627097 @default.
- W2604797481 creator A5033819205 @default.
- W2604797481 creator A5045431644 @default.
- W2604797481 creator A5072568698 @default.
- W2604797481 creator A5074635387 @default.
- W2604797481 creator A5076109830 @default.
- W2604797481 creator A5076253492 @default.
- W2604797481 creator A5084414168 @default.
- W2604797481 date "2013-05-20" @default.
- W2604797481 modified "2023-10-18" @default.
- W2604797481 title "Blinatumomab exposure and pharmacodynamic response in patients with non-Hodgkin lymphoma (NHL)." @default.
- W2604797481 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.3051" @default.
- W2604797481 hasPublicationYear "2013" @default.
- W2604797481 type Work @default.
- W2604797481 sameAs 2604797481 @default.
- W2604797481 citedByCount "11" @default.
- W2604797481 countsByYear W26047974812015 @default.
- W2604797481 countsByYear W26047974812016 @default.
- W2604797481 countsByYear W26047974812017 @default.
- W2604797481 countsByYear W26047974812019 @default.
- W2604797481 countsByYear W26047974812021 @default.
- W2604797481 countsByYear W26047974812023 @default.
- W2604797481 crossrefType "journal-article" @default.
- W2604797481 hasAuthorship W2604797481A5008627097 @default.
- W2604797481 hasAuthorship W2604797481A5033819205 @default.
- W2604797481 hasAuthorship W2604797481A5045431644 @default.
- W2604797481 hasAuthorship W2604797481A5072568698 @default.
- W2604797481 hasAuthorship W2604797481A5074635387 @default.
- W2604797481 hasAuthorship W2604797481A5076109830 @default.
- W2604797481 hasAuthorship W2604797481A5076253492 @default.
- W2604797481 hasAuthorship W2604797481A5084414168 @default.
- W2604797481 hasConcept C111113717 @default.
- W2604797481 hasConcept C112705442 @default.
- W2604797481 hasConcept C126322002 @default.
- W2604797481 hasConcept C159654299 @default.
- W2604797481 hasConcept C203014093 @default.
- W2604797481 hasConcept C2776090121 @default.
- W2604797481 hasConcept C2777288759 @default.
- W2604797481 hasConcept C2778020697 @default.
- W2604797481 hasConcept C2778476748 @default.
- W2604797481 hasConcept C2778690821 @default.
- W2604797481 hasConcept C2778957590 @default.
- W2604797481 hasConcept C2779338263 @default.
- W2604797481 hasConcept C2780850621 @default.
- W2604797481 hasConcept C3875195 @default.
- W2604797481 hasConcept C71924100 @default.
- W2604797481 hasConcept C8891405 @default.
- W2604797481 hasConcept C98274493 @default.
- W2604797481 hasConceptScore W2604797481C111113717 @default.
- W2604797481 hasConceptScore W2604797481C112705442 @default.
- W2604797481 hasConceptScore W2604797481C126322002 @default.
- W2604797481 hasConceptScore W2604797481C159654299 @default.
- W2604797481 hasConceptScore W2604797481C203014093 @default.
- W2604797481 hasConceptScore W2604797481C2776090121 @default.
- W2604797481 hasConceptScore W2604797481C2777288759 @default.
- W2604797481 hasConceptScore W2604797481C2778020697 @default.
- W2604797481 hasConceptScore W2604797481C2778476748 @default.
- W2604797481 hasConceptScore W2604797481C2778690821 @default.
- W2604797481 hasConceptScore W2604797481C2778957590 @default.
- W2604797481 hasConceptScore W2604797481C2779338263 @default.
- W2604797481 hasConceptScore W2604797481C2780850621 @default.
- W2604797481 hasConceptScore W2604797481C3875195 @default.
- W2604797481 hasConceptScore W2604797481C71924100 @default.
- W2604797481 hasConceptScore W2604797481C8891405 @default.
- W2604797481 hasConceptScore W2604797481C98274493 @default.
- W2604797481 hasIssue "15_suppl" @default.
- W2604797481 hasLocation W26047974811 @default.
- W2604797481 hasOpenAccess W2604797481 @default.
- W2604797481 hasPrimaryLocation W26047974811 @default.
- W2604797481 hasRelatedWork W1988935887 @default.
- W2604797481 hasRelatedWork W1990079369 @default.
- W2604797481 hasRelatedWork W2021831895 @default.
- W2604797481 hasRelatedWork W2096040265 @default.
- W2604797481 hasRelatedWork W2152560731 @default.
- W2604797481 hasRelatedWork W2207503964 @default.
- W2604797481 hasRelatedWork W2899072855 @default.
- W2604797481 hasRelatedWork W2922882148 @default.
- W2604797481 hasRelatedWork W2953853904 @default.
- W2604797481 hasRelatedWork W2108030623 @default.
- W2604797481 hasVolume "31" @default.
- W2604797481 isParatext "false" @default.
- W2604797481 isRetracted "false" @default.
- W2604797481 magId "2604797481" @default.
- W2604797481 workType "article" @default.